Bristol Myers Squibb Reports Early Tender Offer Results and Amendments
Summary
Bristol Myers Squibb announced the early participation results, amendments, and early settlement of its cash tender offers for outstanding notes on November 17, 2025 (via Ex. 99.1). On November 18, 2025, the company further announced the accepted amounts and pricing terms of these offers (via Ex. 99.2). - The maximum aggregate purchase price for Pool 1 Notes was decreased from $4,000,000,000 to accept all validly tendered notes by the Early Tender Deadline. - The maximum aggregate purchase price for Pool 2 Notes was increased from $3,000,000,000 to accept all Pool 2 Notes with an acceptance priority level at 1.
Why It Matters
Investors should note the significant adjustments to the tender offer purchase price limits for both Pool 1 and Pool 2 Notes, as detailed in Exhibits 99.1 and 99.2. These changes reflect the company's active debt management strategy and impact its financial structure.
These filing summaries are free and always will be. If this helped you spot material events, consider supporting us.
Want to see how BMY traded around this filing?
Check real-time charts and technical analysis on TradingView to see market reaction to this event.
View BMY Charts on TradingViewAffiliate link
Key Quote
“On November 17, 2025, Bristol-Myers Squibb Company ("Bristol Myers Squibb") issued a press release announcing the early participation results, amendment.”
— From Item 8.01
Filing Details
Reported Items
Additional Information
- CIK Number
- 0000014272
- Filing Date
- Tuesday, November 18, 2025
- Filing Time
- 12:00 AM UTC
- Form Type
- 8-K
- Materiality Level
- high
- Sentiment
- positive